Leadless Cardiac Pacemaker Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Leadless Cardiac Pacemaker Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Leadless cardiac pacemakers are medical devices that are used for the treatment of patients who are suffering from heart-related disorders, like arrhythmias. These pacemakers are expected to transform the cardiac rhythm management (CRM) market in the coming years with their potential to reduce complications and shorter recovery times.

Key Highlights

• The major factors driving the leadless pacemakers (LCP) market are aging population, growing burden of cardiovascular diseases, and technological advancements.
• In addition, other important factors, like avoidance of lead-related complications, such as infection and disfigurement, and technological advancements add advantages to the leadless pacemakers in the market. They are retrievable for a longer time interval post-implantation, which is expected to create substantial opportunities in the market.

Leadless Cardiac Pacemaker Market TrendsMicra Transcatheter Pacing System is Expected to Witness Rapid Growth During the Forecast Period

In Leadless Cardiac Pacemaker Market, Nanostim and Micra TPS are key innovations. Both the devices are single-chamber pacemakers placed directly into the heart with a steerable catheter through the femoral vein. The procedure times with the Micra and Nanostim devices are shorter (lasting from 30 to 45 minutes), than those with the traditional pacemakers. They are self-contained intracardiac devices that include pacemaker electronics, battery, and leads. Both devices can be implanted in the same minimally invasive setting as some traditional pacemakers. Leadless pacemakers are expected to expand their market share rapidly, by displacing traditional cardiac pacemakers, during the forecast period. Micra transcatheter pacing system is in high demand due to rising burden of cardiovascular diseases, minimal post-implantation complications, and easy retrieval, which is expected to fuel the market. However, Abbott recalled its leadless pacemakers from the market following reports of sudden battery depletion. Moreover, in November 2017, Abbott issued a halt on implantations of Nanostim pacemakers, citing docking button issues, which continued till March 2018 but after fixing the issue, the company is working to relaunch the product.

North America is Expected to Dominate the Leadless Cardiac Pacemaker Market

The North American region is expected to dominate the leadless cardiac pacemaker market, due to the high prevalence of cardiovascular diseases, high adoption rates of leadless pacemakers, and availability of reimbursements. furthermore, owing to increasing number of patients suffering from atrial fibrillation and presence of major players in the region is also expected to propel the market growth, over the forecast period.

Leadless Cardiac Pacemaker Market Competitive Analysis

Medical device companies actively participating in the leadless cardiac pacemakers market are Medtronic, EBR Systems Inc, Abbott Laboratories and Boston Scientific Corporation. As of 2019, the leadless pacemaker systems commercially available in the market, having slightly different sizes and implantation requirements, which are Nanostim (Abbott Laboratories) and Micra (Medtronic PLC) and WiSE CRT system (EBR Systems Inc.). However, Boston Scientific, one of the leading pacemaker manufacturers, has been developing its own leadless pacemaker system.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.